Summary & Overview
HCPCS J8530: Cyclophosphamide, Oral 25 mg
HCPCS Level II code J8530 identifies oral cyclophosphamide in 25 mg units, a commonly used alkylating agent in oncology and certain autoimmune conditions. Nationally, accurate coding for oral chemotherapeutic agents matters for claims processing, benefit determination, and patient out-of-pocket cost calculation. This summary addresses the code’s clinical role, billing context, and payer coverage considerations.
Key payers included in the discussion are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code’s clinical application, typical sites of service (outpatient pharmacy and outpatient clinic), and what to expect in claims submission for oral chemotherapy. The publication outlines common billing themes such as unit dosing and medical benefit billing pathways, and highlights where policy updates may affect coverage and prior authorization requirements.
This piece does not provide treatment guidance or individualized recommendation. Data not available in the input is noted where relevant. The content is intended to inform billing, coding accuracy, and payer engagement for organizations managing oral cyclophosphamide therapy.
Billing Code Overview
HCPCS Level II code J8530 represents Cyclophosphamide; oral, 25 mg. This code is used for billing oral cyclophosphamide supplied in 25 mg unit strength.
-
Service type: Oral antineoplastic/chemotherapy medication
-
Typical site of service: Outpatient pharmacy dispensing or physician-administered oral chemotherapy in outpatient clinic settings where oral drugs are billed to medical benefit
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with an autoimmune disease (for example, severe systemic lupus erythematosus or vasculitis) or certain malignancies who receives oral cyclophosphamide for immunosuppression or chemotherapy. The prescribing clinician (rheumatologist, oncologist, or nephrologist) documents indication, dose, and treatment plan in the outpatient chart. A pharmacy dispenses J8530 as the NDC-equivalent HCPCS billing entry for cyclophosphamide oral 25 mg tablets when reporting drug administration or outpatient drug provision to payors. Prior to initiation, baseline labs (CBC, CMP), pregnancy test for women of childbearing potential, and patient counseling about adverse effects and fertility risk are completed. Follow-up visits include interval laboratory monitoring, dosage adjustments, and documentation of adherence and tolerability. Typical site of service is outpatient clinic, infusion center pharmacy pick-up, or patient home with oral self-administration; billing uses the outpatient drug benefit or pharmacy claim mechanisms depending on payor rules.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard service | When no specific modifier applies; submit for routine outpatient drug supply or administration billing |